Company: CERO
Filing Date: 2025-02-05
Form Type: S-1/A
Source: 0001213900-25-010230
Chunk: 371

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-05
Form: S-1/A
Chunk 371
---
      |  19,217,482 |   |
| Cash, restricted cash, and cash equivalents at end of year                               |     | $    |  1,601,255 |   |     | $    |   6,819,564 |   |
| Supplemental disclosure of cash as reported within the audited condensed balance sheets: |     |      |            |   |     |      |             |   |
| Cash                                                                                     |     | $    |  1,518,676 |   |     | $    |   6,651,454 |   |
| Cash equivalents                                                                         |     |      |      2,823 |   |     |      |      88,354 |   |
| Restricted cash                                                                          |     |      |     79,756 |   |     |      |      79,756 |   |
| Cash, cash equivalents, and restricted cash                                              |     |      |  1,601,255 |   |     |      |   6,819,564 |   |

See accompanying notes to financial statements. F-54 CERo Therapeutics, Inc. Notes to Financial Statements NOTE 1 – Organization and Description of the Business Nature of Operations– CERo Therapeutics, Inc. (the “Company”) was incorporated in Delaware on September 23, 2016, and is based in South San Francisco, California. The Company is focused on genetically engineering human immune cells to fight cancer. Since inception, the Company has focused on developing its therapeutic platform and has not yet begun clinical development or product commercialization. Future Company efforts will focus on continued product development, including clinical development, to support regulatory approval to commercialize and subsequent product commercialization. Going concern– The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company’s ability to continue as a going concern is dependent on its ability to raise additional capital to fund its research and development (“R&D”) activities and meet its obligations on a timely basis. Since inception, the Company has incurred net losses and operating cash flow deficits, resulting in an accumulated deficit of $ 43.1million as of December 31, 2023. Additional funds are necessary to maintain current operations and to continue R&D activities. However, there can be no assurance that sufficient funding will be available to allow the Company to successfully continue its R&D